A11811 Controlled clinical trial of Personalized Food Avoidance Dietary Approach to Stop Hypertension (PFADASH): 2 years’ follow-up report

    loading  Checking for direct PDF access through Ovid


Objectives:To validate an inductive model of the diet-genome interaction in the aetiopathogenesis of hypertension, derived from lifelong observation of the dietary determinants of the phenotypic expression of psoriasis (cpcpsoriasis.blogspot.com), with side benefit on blood pressure and related parameters (Chijioke 2012 JHypertension 30).Methods:An open clinical trial involving withdrawal of postulated egregious dietary ingredients. Consenting study participants (SPs) with mild to moderate hypertension (139mmHg < systolic BP < 161mmHg, or on one or more antihypertensives) receive PFADASH counseling with emphasis on avoiding suspected culprit oils and fats. Personalization addresses secondary intolerance to unfamiliar dietary ingredients. Dietary compliance was scored based on the frequency of major or minor dietary indiscretion (‘GOOD’ if less than monthly). SPs with ‘FAIR’ or ‘POOR’ compliance were controls. Antihypertensive drug treatment requirement (ADTR) was measured as unitary dosages x adherence + 0.1 per mmHg that average home BP or automated office BP exceeds 120 systolic.Results:Table 1 is an extract from the comprehensive spreadsheet available from the authors. These data show in SPs with ‘GOOD’ dietary compliance, that BP control is maintained after starting PFADASH, with significant reductions in ADTR, improvement in exercise ability, and of echocardiographic parameters (2-way ANOVA: p < 0.05).Conclusion:The PFADASH excludes much of the modern dietary trend: hence it may not be of therapeutic value in patients lacking motivation. However study participants with ‘GOOD’ PFADASH compliance show marked reduction in ADTR, implying reversibility of hypertension. This supports the postulated diet-genome interaction in the aetiopathogenesis of hypertension.

    loading  Loading Related Articles